Jiao L, Liu X, 2015, Structural Basis of Histone H3K27 Trimethylation by an Active Polycomb Repressive Complex 2. Science (New York, N.Y.), 350(6258): aac4383.

Liu Y, Yang Q, 2023, The Roles of EZH2 in Cancer and Its Inhibitors. Medical Oncology (Northwood, London, England), 40(6): 167.

Papale M, Ferretti E, Battaglia G, et al., 2018, EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers. Frontiers in Pediatrics, 6: 328.

Yuan W, Wu T, Fu H, et al., 2012, Dense Chromatin Activates Polycomb Repressive Complex 2 to Regulate H3 Lysine 27 Methylation. Science (New York, N.Y.), 337(6097): 971–975.

Chittock EC, Latwiel S, Miller TCR, et al., 2017, Molecular Architecture of Polycomb Repressive Complexes. Biochemical Society Transactions, 45(1): 193–205.

Liu X, Liu X, 2022, PRC2, Chromatin Regulation, and Human Disease: Insights From Molecular Structure and Function. Frontiers in Oncology, 12: 894585.

Margueron R, Reinberg D, 2011, The Polycomb Complex PRC2 and Its Mark in Life. Nature, 469(7330): 343–349.

Li CH, Chen Y, 2015, Targeting EZH2 for Cancer Therapy: Progress and Perspective. Current Protein & Peptide Science, 16(6): 559–570.

Guo Y, Zhao S, Wang GG, 2021, Polycomb Gene Silencing Mechanisms: PRC2 Chromatin Targeting, H3K27me3 “Readout,” and Phase Separation-Based Compaction. Trends in Genetics, 37(6): 547–565.

Xu L, Lin J, Deng W, et al., 2020, EZH2 Facilitates BMI1-Dependent Hepatocarcinogenesis Through Epigenetically Silencing MicroRNA-200c. Oncogenesis, 9(11): 101.

He A, Shen X, Ma Q, et al., 2012, PRC2 Directly Methylates GATA4 and Represses Its Transcriptional Activity. Genes & Development, 26(1): 37–42.

Liao Y, Chen CH, Xiao T, et al., 2022, Inhibition of EZH2 Transactivation Function Sensitizes Solid Tumors to Genotoxic Stress. Proceedings of the National Academy of Sciences of the United States of America, 119(3): e2105898119.

Xu K, Wu ZJ, Groner AC, et al., 2012, EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells is Polycomb-Independent. Science (New York, N.Y.), 338(6113): 1465–1469.

Nagy A, Batai B, Kiss L, et al., 2023, Parallel Testing of Liquid Biopsy (ctDNA) and Tissue Biopsy Samples Reveals a Higher Frequency of EZH2 Mutations in Follicular Lymphoma. Journal of Internal Medicine, 294(3): 295–313.

Souroullas GP, Jeck WR, Parker JS, et al., 2016, An Oncogenic EZH2 Mutation Cooperates with Particular Genetic Alterations to Induce Tumors in Mice and Redistributes H3K27 Trimethylation Throughout the Genome. Nature Medicine, 22(6): 632.

Donaldson-Collier MC, Sungalee S, Zufferey M, et al., 2019, EZH2 Oncogenic Mutations Drive Epigenetic, Transcriptional, and Structural Changes Within Chromatin Domains. Nature Genetics, 51(3): 517–528.

Morin RD, Johnson NA, Severson TM, et al., 2010, Somatic Mutation of EZH2 (Y641) in Follicular and Diffuse Large B-Cell Lymphomas of Germinal Center Origin. Nature Genetics, 42(2): 181–185.

McCabe MT, Graves AP, Ganji G, et al., 2012, Mutation of A677 in Histone Methyltransferase EZH2 in Human B-Cell Lymphoma Promotes Hypertrimethylation of Histone H3 on Lysine 27 (H3K27). Proceedings of the National Academy of Sciences of the United States of America, 109(8): 2989–2994.

Nikoloski G, Langemeijer SMC, Kuiper RP, et al., 2010, Somatic Mutations of the Histone Methyltransferase Gene EZH2 in Myelodysplastic Syndromes. Nature Genetics, 42(8): 665–667.

Stasik S, Middeke JM, Kramer M, et al., 2020, EZH2 Mutations and Impact on Clinical Outcome: An Analysis in 1,604 Patients with Newly Diagnosed Acute Myeloid Leukemia. Haematologica, 105(5): e228–e231.

Pan YF, Jin YH, Li HL, et al., 2023, PBRM1-SWI/SNF Complex Contributes to Cell Cycle Control Via E2F1 in Renal Cell Carcinoma Cells. Journal of Zunyi Medical University, 46(2): 105–113.

Kikuchi J, Kinoshita I, Shimizu Y, et al., 2010, Distinctive Expression of the Polycomb Group Proteins BMI1 Polycomb Ring Finger Oncogene and Enhancer of Zeste Homolog 2 in Non-Small Cell Lung Cancers and Their Clinical and Clinicopathologic Significance. Cancer, 116(12): 3015–3024.

Gao B, Liu X, Li Z, et al., 2020, Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer. Frontiers in Oncology, 10: 600514.

Zimmerman SM, Nixon SJ, Chen PY, et al., 2022, EZH2Y641F Mutations Cooperate with STAT3 to Regulate MHC Class I Antigen Processing and Alter the Tumor Immune Response in Melanoma. Oncogene, 41(46): 4983–4993.

Zhang Z, Wang X, Kim M, et al., 2023, Downregulation of EZH2 Inhibits Epithelial-Mesenchymal Transition in Enzalutamide-Resistant Prostate Cancer. The Prostate, 83(15): 1458–1469.

Li F, Wang P, Ye J, et al., 2024, Serum EZH2 is a Novel Biomarker for Bladder Cancer Diagnosis and Prognosis. Frontiers in Oncology, 14: 1303918.

Spangle JM, Roberts TM, Zhao JJ, 2017, The Emerging Role of PI3K/AKT-Mediated Epigenetic Regulation in Cancer. Biochimica Et Biophysica Acta. Reviews on Cancer, 1868(1): 123–131.

Rizk M, Rizq O, Oshima M, et al., 2019, Akt Inhibition Synergizes with Polycomb Repressive Complex 2 Inhibition in the Treatment of Multiple Myeloma. Cancer Science, 110(12): 3695–3707.

Kikuchi J, Koyama D, Wada T, et al., 2015, Phosphorylation-Mediated EZH2 Inactivation Promotes Drug Resistance in Multiple Myeloma. The Journal of Clinical Investigation, 125(12): 4375–4390.

Yang R, Wang M, Zhang G, et al., 2020, E2F7-EZH2 Axis Regulates PTEN/AKT/mTOR Signaling and Glioblastoma Progression. British Journal of Cancer, 123(9): 1445–1455.

Yi C, Li G, Wang W, et al., 2021, Disruption of YY1-EZH2 Interaction Using Synthetic Peptides Inhibits Breast Cancer Development. Cancers, 13(10): 2402.

Sanches JGP, Song B, Zhang Q, et al., 2021, The Role of KDM2B and EZH2 in Regulating the Stemness in Colorectal Cancer Through the PI3K/AKT Pathway. Frontiers in Oncology, 11: 637298.

Du X, Chen Y, Zhang Q, et al., 2020, EZH2 Ameliorates Osteoarthritis by Activating TNFSF13B. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 35(5): 956–965.

Liang G, Han L, Qu M, et al., 2023, Down-Regulation of EZH2 Genes Targeting RUNX3 Affects Proliferation, Invasion, and Metastasis of Human Colon Cancer Cells by Wnt/β-Catenin Signaling Pathway. Aging, 15(23): 13655–13668.

Chen W, Wang HT, Ji JF, et al., 2022, Epigenetic Network of EZH2/SFRP1/Wnt in the Epithelial-Mesenchymal Transition of Laryngeal Carcinoma Cells. Neoplasma, 69(3): 680–690.

Liu L, Xiao B, Hirukawa A, et al., 2023, EZH2 Promotes Mammary Tumor Initiation Through Epigenetic Regulation of the Wnt and mTORC1 Signaling Pathways. Proceedings of the National Academy of Sciences of the United States of America, 120(33): e2303010120.

Yang X, Shao F, Guo D, et al., 2021, WNT/β-Catenin-Suppressed FTO Expression Increases m6A of c-Myc mRNA to Promote Tumor Cell Glycolysis and Tumorigenesis. Cell Death & Disease, 12(5): 462.

Chen S, Sheng C, Liu D, et al., 2013, Enhancer of Zeste Homolog 2 is a Negative Regulator of Mitochondria-Mediated Innate Immune Responses. Journal of Immunology (Baltimore, Md.: 1950), 191(5): 2614–2623.

Le T, He X, Huang J, et al., 2021, Knockdown of Long Noncoding RNA GAS5 Reduces Vascular Smooth Muscle Cell Apoptosis by Inactivating EZH2-Mediated RIG-I Signaling Pathway in Abdominal Aortic Aneurysm. Journal of Translational Medicine, 19(1): 466.

Zeng SHG, Xie JH, Zeng QY, et al., 2021, lncRNA PVT1 Promotes Metastasis of Non-Small Cell Lung Cancer Through EZH2-Mediated Activation of Hippo/NOTCH1 Signaling Pathways. Cell Journal, 23(1): 21–31.

Guan X, Shi A, Zou Y, et al., 2021, EZH2-Mediated microRNA-375 Upregulation Promotes Progression of Breast Cancer via the Inhibition of FOXO1 and the p53 Signaling Pathway. Frontiers in Genetics, 12: 633756.

Lou X, Zhu H, Ning L, et al., 2019, EZH2 Regulates Intestinal Inflammation and Necroptosis Through the JNK Signaling Pathway in Intestinal Epithelial Cells. Digestive Diseases and Sciences, 64(12): 3518–3527.

Chen Z, Du Y, Liu X, et al., 2019, EZH2 Inhibition Suppresses Bladder Cancer Cell Growth and Metastasis Via the JAK2/STAT3 Signaling Pathway. Oncology Letters, 18(1): 907–915.

Tidwell TR, Søreide K, Hagland HR, 2017, Aging, Metabolism, and Cancer Development: from Peto’s Paradox to the Warburg Effect. Aging and Disease, 8(5): 662–676.

Vaupel P, Schmidberger H, Mayer A, 2019, The Warburg Effect: Essential Part of Metabolic Reprogramming and Central Contributor to Cancer Progression. International Journal of Radiation Biology, 95(7): 912–919.

Bian X, Liu R, Meng Y, et al., 2021, Lipid Metabolism and Cancer. The Journal of Experimental Medicine, 218(1): e20201606.

Wang L, Jin Q, Lee JE, et al., 2010, Histone H3K27 Methyltransferase EZH2 Represses Wnt Genes to Facilitate Adipogenesis. Proceedings of the National Academy of Sciences of the United States of America, 107(16): 7317–7322.

Zhang T, Guo Z, Huo X, et al., 2022, Dysregulated Lipid Metabolism Blunts the Sensitivity of Cancer Cells to EZH2 Inhibitor. EBioMedicine, 77: 103872.

Yiew NKH, Greenway C, Zarzour A, et al., 2019, Enhancer of Zeste Homolog 2 (EZH2) Regulates Adipocyte Lipid Metabolism Independent of Adipogenic Differentiation: Role of Apolipoprotein E. The Journal of Biological Chemistry, 294(21): 8577–8591.

Wu X, Li J, Chang K, et al., 2021, Histone H3 Methyltransferase EZH2 Promotes White Adipocytes but Inhibits Brown and Beige Adipocyte Differentiation in Mice. Biochimica Et Biophysica Acta. Molecular and Cell Biology of Lipids, 1866(6): 158901.

Li F, Wu R, Cui X, et al., 2016, Histone Deacetylase 1 (HDAC1) Negatively Regulates Thermogenic Program in Brown Adipocytes via Coordinated Regulation of Histone H3 Lysine 27 (H3K27) Deacetylation and Methylation. The Journal of Biological Chemistry, 291(9): 4523–4536.

Tao T, Chen M, Jiang R, et al., 2017, Involvement of EZH2 in Aerobic Glycolysis of Prostate Cancer Through miR-181b/HK2 Axis. Oncology Reports, 37(3): 1430–1436.

Liu Y, Tu CE, Guo X, et al., 2021, Tumor-Suppressive Function of EZH2 is Through Inhibiting Glutaminase. Cell Death & Disease, 12(11): 975.

Gan L, Li Q, Nie W, et al., 2023, PROX1-Mediated Epigenetic Silencing of SIRT3 Contributes to Proliferation and Glucose Metabolism in Colorectal Cancer. International Journal of Biological Sciences, 19(1): 50–65.

Chang HW, Park JJ, Lee WH, et al., 2024, Enhancer of Zeste Homolog 2 (EZH2)-Dependent Sirtuin-3 Determines Sensitivity to Glucose Starvation in Radioresistant Head and Neck Cancer Cells. Cellular Signalling, 115: 111029.

Zhou J, Lin Y, Kang X, et al., 2023, Hypoxia-Mediated Promotion of Glucose Metabolism in Non-Small Cell Lung Cancer Correlates with Activation of the EZH2/FBXL7/PFKFB4 Axis. Cell Death & Disease, 14(5): 326.

Zingg D, Debbache J, Schaefer SM, et al., 2015, The Epigenetic Modifier EZH2 Controls Melanoma Growth and Metastasis Through Silencing of Distinct Tumor Suppressors. Nature Communications, 6: 6051.

Kuser-Abali G, Zhang Y, Szeto P, et al., 2023, UHRF1/UBE2L6/UBR4-Mediated Ubiquitination Regulates EZH2 Abundance and Thereby Melanocytic Differentiation Phenotypes in Melanoma. Oncogene, 42(17): 1360–1373.

Emran AA, Fisher DE, 2022, Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma. The Journal of Investigative Dermatology, 142(4): 1004–1006.

Li C, Song J, Guo Z, et al., 2022, EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment. Frontiers in Immunology, 13: 857808.

El Baba R, Haidar Ahmad S, Monnien F, et al., 2023, Polyploidy, EZH2 Upregulation, and Transformation in Cytomegalovirus-Infected Human Ovarian Epithelial Cells. Oncogene, 42(41): 3047–3061.

Amin MN, El-Far YM, El-Mowafy M, et al., 2023, Tazemetostat Decreases β-Catenin and CD13 Protein Expression in HEPG-2 and Hepatitis B Virus-Transfected HEPG-2 with Decreased Cell Viability. Clinical Epigenetics, 15(1): 180.

Ding N, You A, Zhao S, et al., 2023, EZH2 Inhibitor Tazemetostat Synergizes with JQ-1 in Esophageal Cancer by Inhibiting c-Myc Signaling Pathway. Medical Oncology (Northwood, London, England), 40(10): 281.

Budagaga Y, Sabet Z, Zhang Y, et al., 2023, Tazemetostat Synergistically Combats Multidrug Resistance by the Unique Triple Inhibition of ABCB1, ABCC1, and ABCG2 Efflux Transporters In Vitro and Ex Vivo. Biochemical Pharmacology, 216: 115769.

Chi SN, Yi JS, Williams PM, et al., 2023, Tazemetostat for Tumors Harboring SMARCB1/SMARCA4 or EZH2 Alterations: Results from NCI-COG Pediatric MATCH APEC1621C. Journal of the National Cancer Institute, 115(11): 1355–1363.

Wang P, Xu L, Fan Y, et al., 2022, EZH2 Inhibitor DZNep Blocks Cell Proliferation of GCB-DLBCL Cells by Upregulating p16. Leukemia & Lymphoma, 63(14): 3370–3377.

Zhou T, Zhang L, He L, et al., 2024, GSK-126 Attenuates Cell Apoptosis in Ischemic Brain Injury by Modulating the EZH2-H3K27me3-Bcl2l1 Axis. Molecular Neurobiology, 61(6): 3369–3383.

Zhu Y, Zhang L, Song X, et al., 2023, Pharmacological Inhibition of EZH2 by ZLD1039 Suppresses Tumor Growth and Pulmonary Metastasis in Melanoma Cells In Vitro and In Vivo. Biochemical Pharmacology, 210: 115493.

Mei H, Wu H, Yang J, et al., 2023, Discovery of IHMT-337 as a Potent Irreversible EZH2 Inhibitor Targeting CDK4 Transcription for Malignancies. Signal Transduction and Targeted Therapy, 8: 18.

Li X, Wang C, Li S, et al., 2024, Dual Target PARP1/EZH2 Inhibitors Inducing Excessive Autophagy and Producing Synthetic Lethality for Triple-Negative Breast Cancer Therapy. European Journal of Medicinal Chemistry, 265: 116054.

Chandnani N, Choudhari VS, Talukdar R, et al., 2023, Depletion of Enhancer Zeste Homolog 2 (EZH2) Directs Transcription Factors Associated with T Cell Differentiation Through Epigenetic Regulation of Yin Yang 1 (YY1) in Combating Non-Small Cell Lung Cancer (NSCLC). Medical Oncology (Northwood, London, England), 40(7): 185.

Wang J, Yang C, Xu H, et al., 2024, The Interplay Between HIF-1α and EZH2 in Lung Cancer and Dual-Targeted Drug Therapy. Advanced Science (Weinheim, Baden-Wurttemberg, Germany), 11(7): e2303904.

Huang N, Liao P, Zuo Y, et al., 2023, Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors. Journal of Medicinal Chemistry, 66(4): 2646–2662.

Adelaiye-Ogala R, Budka J, Damayanti NP, et al., 2017, EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. Cancer Research, 77(23): 6651–6666.

Guo W, Wang Y, Yang M, et al., 2021, LincRNA-Immunity Landscape Analysis Identifies EPIC1 as a Regulator of Tumor Immune Evasion and Immunotherapy Resistance. Science Advances, 7(7): eabb3555.

Ratz L, Brambillasca C, Bartke L, et al., 2022, Combined Inhibition of EZH2 and ATM is Synthetic Lethal in BRCA1-Deficient Breast Cancer. Breast Cancer Research: BCR, 24(1): 41.

Negri A, Marozzi M, Trisciuoglio D, et al., 2023, Simultaneous Administration of EZH2 and BET Inhibitors Inhibits Proliferation and Clonogenic Ability of Metastatic Prostate Cancer Cells. Journal of Enzyme Inhibition and Medicinal Chemistry, 38(1): 2163242.

Yu H, Ma M, Yan J, et al., 2017, Identification of Coexistence of BRAF V600E Mutation and EZH2 Gain Specifically in Melanoma as a Promising Target for Combination Therapy. Journal of Translational Medicine, 15(1): 243.